Skip to main content
. 2019 Mar 1;10(4):333–339. doi: 10.6004/jadpro.2019.10.4.2

Figure 3.

Figure 3.

Best overall response of patients with metastatic clear cell renal cell carcinoma treated with cabozantinib at The University of Texas MD Anderson Cancer Center from 2015 to 2017. PD = progressive disease; SD = stable disease; PR = partial response.